Bacterin Announces Strategic Alliance to Distribute Products into European Markets
November 07 2013 - 7:30AM
Business Wire
Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader
in the development of revolutionary bone graft materials and
coatings for medical applications, today announced a strategic
alliance with DMP Spine Biologics (DMP) for distribution of
Bacterin’s proprietary biologic products in the European Union. We
anticipate that Bacterin products will be well received in many new
markets with its strong brand, supportive clinical studies and
DMP’s vast network of relationships.
Daniel Goldberger, Bacterin’s CEO, commented “We are pleased to
have established this strategic relationship with DMP. They have
extensive relationships throughout Europe and have a vast
knowledge of the orthopedic and spine markets in various countries.
The European markets represent a significant opportunity for our
products. This relationship will allow us to enter the European
market and expand our business internationally.”
Marios Papadopoulos, Chairman and CEO of DMP Spine Technologies
concurred “We could not be more excited about this opportunity to
work with such an innovative, US-based tissue bank, with an
incredible portfolio of products and knowledgeable management team.
We have already engaged distributors through our network and will
be expanding distribution into various EU countries in the very
near future.”
With the successful expansion of our ISO certification earlier
this year, Bacterin is well positioned for international expansion.
Growth through this new distribution channel will contribute to
Bacterin’s current international strategy and will be incremental
business for the organization.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops,
manufactures and markets biologics products to domestic and
international markets. These products are used in a variety of
applications including enhancing fusion in spine surgery, relief of
back pain, promotion of bone growth in foot and ankle surgery,
promotion of cranial healing following neurosurgery and subchondral
repair in knee and other joint surgeries.
Bacterin’s Medical Device division develops, employs, and
licenses coatings for various medical device applications. For
further information, please visit www.bacterin.com.
About DMP Spine Investments Inc.
DMP Spine Investments, Inc. is a US corporation established with
a focus to provide US based products to European markets. The
principals have extensive distribution experience in Europe, having
spent over 30 years distributing for major US orthopedic and spine
manufacturers. DMP has a strong network of leading US and
International spine and orthopedic surgeons, with relationships and
access to markets throughout Europe, the Middle East and
Commonwealth of Independent States (CIS) countries.
Important Cautions Regarding Forward-looking
Statements
This news release contains certain disclosures that may be
deemed forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to
significant risks and uncertainties. Forward-looking statements
include statements that are predictive in nature, that depend upon
or refer to future events or conditions, or that include words such
as “continue,” “efforts,” “expects,” “anticipates,” “intends,”
“plans,” “believes,” “estimates,” “projects,” “forecasts,”
“strategy,” “will,” “goal,” “target,” “prospects,” “potential,”
“optimistic,” “confident,” “likely,” “probable” or similar
expressions or the negative thereof. Statements of historical fact
also may be deemed to be forward-looking statements. We caution
that these statements by their nature involve risks and
uncertainties, and actual results may differ materially depending
on a variety of important factors, including, among others: the
Company’s ability to meet its existing and anticipated contractual
obligations, including financial covenant and other obligations
contained in the Company’s secured lending facility; the Company’s
ability to manage cash flow and achieve profitability; the
Company’s ability to develop, market, sell and distribute desirable
applications, products and services and to protect its intellectual
property; the ability of the Company’s sales force to achieve
expected results; the ability of the Company’s customers to pay and
the timeliness of such payments; the Company’s ability to obtain
financing as and when needed; changes in consumer demands and
preferences; the Company’s ability to attract and retain management
and employees with appropriate skills and expertise; the Company’s
ability to successfully conclude government investigations; the
impact of changes in market, legal and regulatory conditions and in
the applicable business environment, including actions of
competitors; and other factors. Additional risk factors are listed
in the Company’s Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q under the heading “Risk Factors.” The Company
undertakes no obligation to release publicly any revisions to any
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events, except as required by law.
Cockrell GroupRich Cockrell,
877-889-1972investorrelations@thecockrellgroup.comcockrellgroup.com